<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Frutiger-UltraBlack,Bold" color="#336fb7"/>
	<fontspec id="font1" size="9" family="Frutiger-UltraBlack,Bold" color="#007b83"/>
	<fontspec id="font2" size="9" family="Courier" color="#007b83"/>
	<fontspec id="font3" size="9" family="Frutiger-Light" color="#231f20"/>
	<fontspec id="font4" size="9" family="Arial" color="#000000"/>
	<fontspec id="font5" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font6" size="20" family="Frutiger-UltraBlack,Bold" color="#000000"/>
	<fontspec id="font7" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font8" size="14" family="GillSans-Light" color="#000000"/>
	<fontspec id="font9" size="16" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font10" size="15" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font11" size="11" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font12" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font13" size="6" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font14" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font15" size="10" family="GillSans" color="#000000"/>
	<fontspec id="font16" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font17" size="8" family="GillSans" color="#000000"/>
	<fontspec id="font18" size="8" family="GillSans,Italic" color="#000000"/>
	<fontspec id="font19" size="8" family="GillSans,Bold" color="#000000"/>
<text top="44" left="508" width="67" height="9" font="font0" id="p1_t1" reading_order_no="2" segment_no="1" tag_type="title">Bio Med Central<a href="http://www.biomedcentral.com/"><b>Bio</b></a></text>
<text top="756" left="508" width="46" height="10" font="font4" id="p1_t2" reading_order_no="60" segment_no="21" tag_type="text">Page 1 of 9<a href="http://www.biomedcentral.com/"><b>Med</b></a></text>
<text top="769" left="432" width="122" height="8" font="font5" id="p1_t3" reading_order_no="61" segment_no="22" tag_type="text">(page number not for citation purposes)<a href="http://www.biomedcentral.com/">Central</a></text>
<text top="19" left="55" width="387" height="19" font="font6" id="p1_t4" reading_order_no="0" segment_no="0" tag_type="title">Australia and New Zealand Health</text>
<text top="39" left="55" width="67" height="19" font="font6" id="p1_t5" reading_order_no="1" segment_no="0" tag_type="title">Policy<i>(page number not for citation purposes)</i></text>
<text top="86" left="502" width="79" height="10" font="font7" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="title">Open Access<b>Australia and New Zealand Health </b></text>
<text top="87" left="55" width="40" height="13" font="font8" id="p1_t7" reading_order_no="4" segment_no="3" tag_type="title">Review<b>Policy</b></text>
<text top="105" left="55" width="491" height="15" font="font9" id="p1_t8" reading_order_no="5" segment_no="4" tag_type="title">Assessing the impact of prescribed medicines on health outcomes<a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="122" left="55" width="229" height="14" font="font10" id="p1_t9" reading_order_no="6" segment_no="5" tag_type="text">Wayne D Hall* 1,2 and Jayne Lucke 1</text>
<text top="157" left="55" width="499" height="9" font="font12" id="p1_t10" reading_order_no="7" segment_no="6" tag_type="text">Address: 1 School of Population Health, University of Queensland, Herston QLD, 4006, Australia and 2 Population Health and Uses of Medicines<b>Assessing the impact of prescribed medicines on health outcomes</b></text>
<text top="167" left="55" width="191" height="8" font="font12" id="p1_t11" reading_order_no="8" segment_no="6" tag_type="text">Unit, University of New South Wales, Sydney, Australia</text>
<text top="182" left="55" width="294" height="8" font="font12" id="p1_t12" reading_order_no="9" segment_no="7" tag_type="text">Email: Wayne D Hall* - w.hall@sph.uq.edu.au; Jayne Lucke - j.lucke@sph.uq.edu.au</text>
<text top="193" left="55" width="92" height="8" font="font12" id="p1_t13" reading_order_no="10" segment_no="8" tag_type="text">* Corresponding author</text>
<text top="341" left="112" width="44" height="10" font="font14" id="p1_t14" reading_order_no="20" segment_no="16" tag_type="title">Abstract</text>
<text top="356" left="112" width="386" height="9" font="font15" id="p1_t15" reading_order_no="21" segment_no="17" tag_type="text">This paper reviews methods that can be used to assess the impact of medicine use on population</text>
<text top="368" left="112" width="386" height="9" font="font15" id="p1_t16" reading_order_no="22" segment_no="17" tag_type="text">health outcomes. In the absence of a gold standard, we argue that a convergence of evidence from</text>
<text top="380" left="112" width="386" height="9" font="font15" id="p1_t17" reading_order_no="23" segment_no="17" tag_type="text">different types of studies using multiple methods of independent imperfection provides the best</text>
<text top="391" left="112" width="386" height="9" font="font15" id="p1_t18" reading_order_no="24" segment_no="17" tag_type="text">bases for attributing improvements in health outcomes to the use of medicines. The major</text>
<text top="403" left="112" width="386" height="9" font="font15" id="p1_t19" reading_order_no="25" segment_no="17" tag_type="text">requirements are: good evidence that a safe and effective medicine is being appropriately</text>
<text top="415" left="112" width="385" height="9" font="font15" id="p1_t20" reading_order_no="26" segment_no="17" tag_type="text">prescribed; covariation between medicine use and improved health outcomes; and being able to</text>
<text top="427" left="112" width="385" height="9" font="font15" id="p1_t21" reading_order_no="27" segment_no="17" tag_type="text">discount alternative explanations of the covariation (via covariate adjustment, propensity analyses</text>
<text top="438" left="112" width="386" height="9" font="font15" id="p1_t22" reading_order_no="28" segment_no="17" tag_type="text">and sensitivity analyses), so that medicine use is the most plausible explanation of the improved</text>
<text top="450" left="112" width="386" height="9" font="font15" id="p1_t23" reading_order_no="29" segment_no="17" tag_type="text">health outcomes. The strongest possible evidence would be provided by the coherence of the<b>Abstract</b></text>
<text top="462" left="112" width="386" height="9" font="font15" id="p1_t24" reading_order_no="30" segment_no="17" tag_type="text">following types of evidence: (1) individual linked data showing that patients are prescribed the</text>
<text top="474" left="112" width="386" height="9" font="font15" id="p1_t25" reading_order_no="31" segment_no="17" tag_type="text">medicine, there are reasonable levels of patient compliance, and there is a relationship between</text>
<text top="485" left="112" width="386" height="9" font="font15" id="p1_t26" reading_order_no="32" segment_no="17" tag_type="text">medicine use and health improvements that is not explained by other factors; (2) ecological</text>
<text top="497" left="112" width="385" height="9" font="font15" id="p1_t27" reading_order_no="33" segment_no="17" tag_type="text">evidence of improvements in these health outcomes in the population in which the medicine is</text>
<text top="509" left="112" width="386" height="9" font="font15" id="p1_t28" reading_order_no="34" segment_no="17" tag_type="text">used. Confidence in these inferences would be increased by: the replication of these results in</text>
<text top="521" left="112" width="386" height="9" font="font15" id="p1_t29" reading_order_no="35" segment_no="17" tag_type="text">comparable countries and consistent trends in population vital statistics in countries that have</text>
<text top="532" left="112" width="386" height="9" font="font15" id="p1_t30" reading_order_no="36" segment_no="17" tag_type="text">introduced the medicine; and epidemiological modelling indicating that changes observed in</text>
<text top="544" left="112" width="378" height="9" font="font15" id="p1_t31" reading_order_no="37" segment_no="17" tag_type="text">population health outcomes are plausible given the epidemiology of the condition being treated.</text>
<text top="594" left="55" width="60" height="10" font="font14" id="p1_t32" reading_order_no="38" segment_no="19" tag_type="title">Background</text>
<text top="605" left="55" width="241" height="9" font="font16" id="p1_t33" reading_order_no="39" segment_no="20" tag_type="text">Many developed countries publicly subsidize selected</text>
<text top="617" left="55" width="241" height="9" font="font16" id="p1_t34" reading_order_no="40" segment_no="20" tag_type="text">medicines on the assumption that their use will improve</text>
<text top="629" left="55" width="241" height="9" font="font16" id="p1_t35" reading_order_no="41" segment_no="20" tag_type="text">the health of patients who take these drugs [1]. Improved</text>
<text top="640" left="55" width="241" height="9" font="font16" id="p1_t36" reading_order_no="42" segment_no="20" tag_type="text">health outcomes might include: reduced incidence of dis-</text>
<text top="652" left="55" width="241" height="9" font="font16" id="p1_t37" reading_order_no="43" segment_no="20" tag_type="text">ease (if medicines prevent new cases of disease in persons</text>
<text top="664" left="55" width="241" height="9" font="font16" id="p1_t38" reading_order_no="44" segment_no="20" tag_type="text">at risk); reduced mortality and morbidity (if medicines are</text>
<text top="676" left="55" width="241" height="9" font="font16" id="p1_t39" reading_order_no="45" segment_no="20" tag_type="text">used to treat early or established cases of a disease); and</text>
<text top="687" left="55" width="241" height="9" font="font16" id="p1_t40" reading_order_no="46" segment_no="20" tag_type="text">reduced morbidity and disability or improved quality of</text>
<text top="699" left="55" width="241" height="9" font="font16" id="p1_t41" reading_order_no="47" segment_no="20" tag_type="text">life (if medicines are used to slow the progression or pal-<b>Background</b></text>
<text top="711" left="55" width="193" height="9" font="font16" id="p1_t42" reading_order_no="48" segment_no="20" tag_type="text">liate the symptoms of an established disease).</text>
<text top="593" left="313" width="241" height="9" font="font16" id="p1_t43" reading_order_no="49" segment_no="18" tag_type="text">Drugs are usually only subsidised if they have been shown</text>
<text top="605" left="313" width="241" height="9" font="font16" id="p1_t44" reading_order_no="50" segment_no="18" tag_type="text">to be safe and effective in randomised controlled trials<a href="">[1</a>]. Improved</text>
<text top="617" left="313" width="241" height="9" font="font16" id="p1_t45" reading_order_no="51" segment_no="18" tag_type="text">(RCTs). Although data from RCTs provides good reasons</text>
<text top="629" left="313" width="241" height="9" font="font16" id="p1_t46" reading_order_no="52" segment_no="18" tag_type="text">for expecting that widely prescribed medicines may</text>
<text top="640" left="313" width="241" height="9" font="font16" id="p1_t47" reading_order_no="53" segment_no="18" tag_type="text">improve health outcomes, the improved health outcomes</text>
<text top="652" left="313" width="241" height="9" font="font16" id="p1_t48" reading_order_no="54" segment_no="18" tag_type="text">observed in such trials may not occur in routine clinical</text>
<text top="664" left="313" width="241" height="9" font="font16" id="p1_t49" reading_order_no="55" segment_no="18" tag_type="text">use. Controlled clinical trials may provide optimistic esti-</text>
<text top="676" left="313" width="241" height="9" font="font16" id="p1_t50" reading_order_no="56" segment_no="18" tag_type="text">mates of effectiveness under routine clinical care because</text>
<text top="687" left="313" width="241" height="9" font="font16" id="p1_t51" reading_order_no="57" segment_no="18" tag_type="text">the medicines are used to treat more seriously ill patients</text>
<text top="699" left="313" width="241" height="9" font="font16" id="p1_t52" reading_order_no="58" segment_no="18" tag_type="text">in the community than were studied in clinical trials [2,3].</text>
<text top="711" left="313" width="241" height="9" font="font16" id="p1_t53" reading_order_no="59" segment_no="18" tag_type="text">Drugs may also not be prescribed, they may be prescribed</text>
<text top="236" left="55" width="92" height="7" font="font17" id="p1_t54" reading_order_no="11" segment_no="9" tag_type="text">Published: 15 February 2007</text>
<text top="250" left="55" width="155" height="7" font="font18" id="p1_t55" reading_order_no="12" segment_no="12" tag_type="text">Australia and New Zealand Health Policy 2007, 4 :1</text>
<text top="250" left="219" width="88" height="7" font="font17" id="p1_t56" reading_order_no="13" segment_no="12" tag_type="text">doi:10.1186/1743-8462-4-1</text>
<text top="236" left="325" width="84" height="7" font="font17" id="p1_t57" reading_order_no="18" segment_no="10" tag_type="text">Received: 25 August 2006</text>
<text top="245" left="325" width="92" height="7" font="font17" id="p1_t58" reading_order_no="19" segment_no="11" tag_type="text">Accepted: 15 February 2007</text>
<text top="264" left="55" width="244" height="7" font="font17" id="p1_t59" reading_order_no="14" segment_no="13" tag_type="text">This article is available from: http://www.anzhealthpolicy.com/content/4/1/1</text>
<text top="279" left="55" width="174" height="7" font="font17" id="p1_t60" reading_order_no="15" segment_no="14" tag_type="text">Â© 2007 Hall and Lucke; licensee BioMed Central Ltd.</text>
<text top="288" left="55" width="492" height="7" font="font17" id="p1_t61" reading_order_no="16" segment_no="15" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),<a href="">in clinical trials [2,3].</a></text>
<text top="297" left="55" width="400" height="7" font="font17" id="p1_t62" reading_order_no="17" segment_no="15" tag_type="text">which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
</page>
</pdf2xml>
